Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1

Author： Pastores Gregory M Barnett Natalie L

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.2, 2003-02, pp. : 273-281

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacological chaperone therapy for Gaucher disease: a patent review

By Benito Juan M Garcíía Fernáández Joséé M Mellet Carmen Ortiz

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 6, 2011-06 ,pp. : 885-903

Informa Healthcare

Access to resources Recommend Favorite

Role of Dual Antiplatelet Therapy in Symptomatic Patients with Established Vascular Disease: Putting the CHARISMA Trial into Therapeutic Perspective

By Boden William Flather Marcus Bhatt Deepak

Cardiovascular Drugs and Therapy, Vol. 24, Iss. 3, 2010-06 ,pp. : 207-216

Springer Publishing Company

Access to resources Recommend Favorite

Miglustat

By McCormack P.L. Goa K.L.

Drugs, Vol. 63, Iss. 22, 2003-01 ,pp. : 2427-2434

Adis International

Access to resources Recommend Favorite

Alglucerase/imiglucerase withdrawal: Skeletal (first report) and haematological manifestations, organomegaly and growth delays in children with type 1 Gaucher's disease: 4 case reports

Reactions Weekly, Vol. 1, Iss. 1173, 2007-01 ,pp. : 4-5

Adis International

Access to resources Recommend Favorite

Substrate reduction therapy for glycosphingolipid storage disorders

By Lachmann R.H. Platt F.M.

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 3, 2001-03 ,pp. : 455-466

Informa Healthcare

Access to resources Recommend Favorite